

The Manager  
 Company Announcements Office  
 ASX Limited

## JUNE QUARTER 2014 APPENDIX 4C

**31 July 2014, ADELAIDE:** LBT Innovations Ltd (ASX: LBT) announces its fourth quarter cash flow report for the year ending 30 June 2014.

### Highlights:

- Cash at the end of June 2014 \$1.791 million (an increase of \$0.798 million on the balance at the end of March 2014).
- Receipt of \$1 million milestone (third APAS milestone) under the 50:50 joint venture agreement with Hettich AG Switzerland.
- Receipt of \$398,600 (before fees) from the 1st tranche of the \$1.5 million share placement announced on June 18<sup>th</sup> 2014
- Receipt of royalty income under the agreement with bioMérieux. The receipt of \$US150,000 represents the first quarter 2014 calendar year royalty payment. Minimum royalties for the full 2014 calendar year will total \$US600,000.
- Receipt of \$127,597 from Austrade for 2012/13 under the Export Market Development Grant.

Other cash flows for the quarter related to normal operating activities.

In July 2014, LBT received \$US150,000 representing the second quarter of the royalty payment due for the 2014 calendar year from bioMérieux.

The company is in the process of completing the capital raising announced on June 18<sup>th</sup> 2014. A further \$1.1 million (before fees) from Tranche 2 of the share placement is expected to be received in August and is subject to shareholder approval at the EGM scheduled for August 1 2014. In addition, a further \$517,450 (before fees) has been raised from the Share Purchase Plan which closed on July 17<sup>th</sup>. Share from both these raisings are expected to be allotted in early August

– ENDS –

### About LBT Innovations

LBT Innovations (LBT) is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company has two breakthrough products in microbiology automation: PREVI® Isola, which provides automation of culture plate streaking, and APAS®, a breakthrough in automated culture plate reading, interpretation and reporting. LBT also has a third product in development, Woundvue™, a proposed automation solution to assist in the management of chronic wounds.

LBT has an exclusive global licence agreement with French diagnostics company bioMérieux to manufacture and market PREVI® Isola. LBT receives ongoing royalty payments for PREVI Isola, which has been installed in clinical laboratories around the world. LBT's APAS® technology (the Automated Plate Assessment System) is nearing market. Based upon LBT's innovative intelligent image interpretation platform, APAS specifically addresses the automated imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a Joint Venture with Hettich AG Switzerland to drive the commercial development and global distribution of APAS instrumentation and software products.

For more information, see [www.lbtinnovations.com](http://www.lbtinnovations.com)

### CONTACTS

| LBT Innovations  | Media Relations  |
|--|--|
| Lusia Guthrie<br>CEO<br>Tel: +61 (0)8 8227 1555<br>E: <a href="mailto:info@lbtinnovations.com">info@lbtinnovations.com</a> | Rudi Michelson<br>Monsoon Communications<br>Tel: +61 (0)3 9620 3333<br>E: <a href="mailto:rudim@monsoon.com.au">rudim@monsoon.com.au</a> |

# Appendix 4C

## Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005.

Name of entity

LBT Innovations Ltd

ABN

95 107 670 673

Quarter ended ("current quarter")

30 June 2014

### Consolidated statement of cash flows

| Cash flows related to operating activities |   | Current quarter | Year to date<br>(12 months) |
|--|---|-----------------|-----------------------------|
|  |   | \$A             | \$A                         |
| 1.1  | Receipts from customers                               |                 |                             |
| 1.2  | Payments for  |                 |                             |
|  | (a) staff costs                                       | (372,356)       | (1,329,237)                 |
|  | (b) advertising and marketing                         | (3,517)         | (35,687)                    |
|  | (c) research and development                          | (477,991)       | (4,392,034)                 |
|  | (d) leased assets                                     |                 |                             |
|  | (e) other working capital                             | (18,749)        | (258,544)                   |
| 1.3  | Dividends received                                    |                 |                             |
| 1.4  | Interest and other items of a similar nature received | 2,881           | 43,475                      |
| 1.5  | Interest and other costs of finance paid              |                 |                             |
| 1.6  | Income taxes paid                                     |                 |                             |
|  | Income tax received (R & D Tax Concession)            | 0               | 826,942                     |
| 1.7  | Other (provide details if material)                   |                 |                             |
|  | Signing Fee (Joint Venture Agreement)                 | 0               | 2,000,000                   |
|  | Milestone Payment (Joint Venture Agreement)           | 1,000,000       | 3,000,000                   |
|  | Royalties (PREVI® Isola)                              | 161,394         | 650,365                     |
|  | Royalty Payment                                       | (12,427)        | (61,791)                    |
|  | Export Market Development Grant                       | 127,597         | 127,597                     |
| 24   | <b>Net operating cash flows</b>                       | 406,832         | 571,086                     |

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

|  | Current quarter<br>\$A | Year to date<br>(12 months)<br>\$A |
|--|------------------------|------------------------------------|
| 1.8 Net operating cash flows (carried forward)                           | 406,832                | 571,086                            |
| <b>1.9 Cash flows related to investing activities</b>                    |                        |                                    |
| Payment for acquisition of:  |                        |                                    |
| (a) businesses (item 5)  |                        |                                    |
| (b) equity investments   |                        |                                    |
| (c) intellectual property  |                        |                                    |
| (d) physical non-current assets  | (6,397)                | (72,176)                           |
| (e) other non-current assets development expenditure                     |                        |                                    |
| <b>1.10 Proceeds from disposal of:</b>                                   |                        |                                    |
| (a) businesses (item 5)  |                        |                                    |
| (b) equity investments   |                        |                                    |
| (c) intellectual property  |                        |                                    |
| (d) physical non-current assets  | (311)                  | 53                                 |
| (e) other non-current assets (APAS® Beta)                                | 35,000                 | 35,000                             |
| 1.11 Loans to other entities   |                        |                                    |
| 1.12 Loans repaid by other entities                                      |                        |                                    |
| 1.13 Other (provide details if material) Patent Costs / Trade Mark Costs |                        |                                    |
| <b>Net investing cash flows</b>  | 28,292                 | (37,123)                           |
| <b>1.14 Total operating and investing cash flows</b>                     | 435,124                | 533,963                            |
| <b>Cash flows related to financing activities</b>                        |                        |                                    |
| 1.15 Proceeds from issues of shares, options, etc.                       | 398,600                | 415,400                            |
| 1.16 Proceeds from sale of forfeited shares                              |                        |                                    |
| 1.17 Proceeds from borrowings  |                        |                                    |
| 1.18 Repayment of borrowings   |                        |                                    |
| 1.19 Dividends paid  |                        |                                    |
| 1.20 Other (Share registry fees & capital raising costs)                 | (23,916)               | (25,491)                           |
| <b>Net financing cash flows</b>  | 374,684                | 389,909                            |
| <b>Net increase (decrease) in cash held</b>                              | 809,808                | 923,872                            |
| 1.21 Cash at beginning of quarter/year to date                           | 992,968                | 875,864                            |
| 1.22 Exchange rate adjustments   | (12,014)               | (8,974)                            |
| <b>1.23 Cash at end of quarter</b>                                       | 1,790,762              | 1,790,762                          |

+ See chapter 19 for defined terms.

**Payments to directors of the entity and associates of the directors**

**Payments to related entities of the entity and associates of the related entities**

|      |  | Current quarter<br>\$A |
|------|--|------------------------|
| 1.24 | Aggregate amount of payments to the parties included in item 1.2 | 134,463                |
| 1.25 | Aggregate amount of loans to the parties included in item 1.11   | -                      |

1.26 Explanation necessary for an understanding of the transactions

**Directors Fees**

Item 1.24 includes remuneration paid to the Directors including remuneration paid to the Managing Director.

**Non-cash financing and investing activities**

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

---

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

---

**Financing facilities available**

*Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).*

|                                 | Amount available<br>\$A | Amount used<br>\$A |
|---------------------------------|-------------------------|--------------------|
| 3.1 Loan facilities             |                         |                    |
| 3.2 Credit standby arrangements | 40,000                  | 5,311              |

**Reconciliation of cash**

| Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows. | Current quarter<br>\$A | Previous quarter<br>\$A |
|---|------------------------|-------------------------|
| 4.1 Cash on hand and at bank  | 1,775,762              | 977,968                 |
| 4.2 Deposits at call  |                        |                         |
| 4.3 Bank overdraft  |                        |                         |
| 4.4 Other (Term Deposits)   | 15,000                 | 15,000                  |
| <b>Total: cash at end of quarter</b> (item 1.23)  | 1,790,762              | 992,968                 |

**Acquisitions and disposals of business entities**

|   | Acquisitions<br>(Item 1.9(a)) | Disposals<br>(Item 1.10(a)) |
|---|-------------------------------|-----------------------------|
| 5.1 Name of entity                            | N/A                           | N/A                         |
| 5.2 Place of incorporation or registration    |                               |                             |
| 5.3 Consideration for acquisition or disposal |                               |                             |
| 5.4 Total net assets                          |                               |                             |
| 5.5 Nature of business                        |                               |                             |

---

+ See chapter 19 for defined terms.

## Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here:  ..... Date: 31/07/2014

Print name: Lusia Guthrie

## Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 1026: Statement of Cash Flows* apply to this report except for the paragraphs of the Standard set out below.
  - 6.2 - reconciliation of cash flows arising from operating activities to operating profit or loss
  - 9.2 - itemised disclosure relating to acquisitions
  - 9.4 - itemised disclosure relating to disposals
  - 12.1(a) - policy for classification of cash items
  - 12.3 - disclosure of restrictions on use of cash
  - 13.1 - comparative information
3. **Accounting Standards.** ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

---

+ See chapter 19 for defined terms.